---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Planned confirmatory trial"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Planned confirmatory trial. Covers Location and study date, Study design, Treatment, Study outcomes, Statistical analysis description, and Study limitations. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence/planned-confirmatory-trial"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Planned confirmatory trial

<a id="heading-3.1.4"></a>

## 3.1.4 Planned Confirmatory Trial

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

No evidence found.

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Screening to begin in the United States by the end of 2026

> “The Company plans to initiate patient screening in the U.S. by the end of 2026.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

> “The Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Randomized, standard-of-care-controlled design, November 2026

> “The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) as the primary endpoint at 36 months.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-3.1.4.3-2"></a>

#### Standard-of-care control considered after the June 2026 Type B meeting, July 2026

> “In addition, the FDA seeks to align on the confirmatory study design prior to the BLA submission, including consideration of a randomized standard-of-care control design instead of a sham procedure.”
> “The Company plans to initiate the confirmatory study as expeditiously as possible after aligning with the FDA on the trial design.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-3.1.4.3-3"></a>

#### Sham surgery-controlled study recommended after the January 2026 Type A meeting, superseded in June 2026

> “In January 2026, we met with the FDA at a Type A meeting to discuss AMT-130.”
> “The FDA strongly recommended we conduct a prospective, randomized, double-blind, sham surgery-controlled study.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Ifezuntirgene inilparvovec or standard of care, randomized 2:1

> “The study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Total Functional Capacity as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Total Functional Capacity in the phase I/II data at 48 months

> “Total Functional Capacity (TFC), the primary measure for the confirmatory study, showed a 61% slowing (nominal p=0.008) at 48 months.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-3.1.4.6.1-2"></a>

##### Rate of decline by baseline Total Functional Capacity

> “The annual rate of decline for 575 patients with baseline TFC scores of 7 to 13 was 0.97 (SE 0.06), was 0.38 (SE 0.08) for 270 patients with baseline TFC scores of 3 to 6, and was 0.06 (SE 0.1) for 101 patients with TFC scores of 0 to 2.”
> “These rates of functional decline and the covariates that modify them should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease.”

Source: [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)

<a id="topic-3.1.4.6.1-3"></a>

##### Absence of placebo response on Total Functional Capacity: GENERATION HD1 placebo arm

> “The progression measured by Total Functional Capacity (TFC) in the GENERATION HD1 placebo arm aligned with predicted natural history (within 95% CI), indicating no significant placebo response.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-3.1.4.6.1-4"></a>

##### Functional ability as a regulatory outcome and ceiling effects in early disease

> “The assessment of functional ability as a clinical outcome is deemed essential for therapeutic approval by regulatory agencies such as the FDA.”
> “In addition, these scales have limiting ceiling effects that make them unattractive for use in earlier stages of HD.”

Source: [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)

<a id="topic-3.1.4.6.1-5"></a>

##### Total Functional Capacity at 65 weeks as the main measure of effectiveness in the Nurzigma application

> “The company presented results from a main study involving 499 adults aged 25 years and older with early Huntington’s disease.”
> “The main measure of effectiveness was the change in the total functional capacity (TFC) score after 65 weeks of treatment.”
> “The TFC score measures how well a person with a disease that affects the nervous system can perform daily tasks and activities.”

Source: [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)

<a id="topic-3.1.4.6.1-6"></a>

##### Internal consistency of the UHDRS domains, including functional capacity

> “The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity.”
> “We found there was a high degree of internal consistency within each of the domains of the UHDRS and that there were significant intercorrelations between the domains of the UHDRS, with the exception of the total behavioral score.”

Source: [Huntington Study Group (1996)](https://pubmed.ncbi.nlm.nih.gov/8684382/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Approximately 200 participants planned

> “The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Function Capacity (“TFC”) as the primary endpoint at 36 months.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- Planned design only: the trial is described in company releases and the Form 10-Q as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint, and screening is planned to begin in the United States by the end of 2026.
- Control without a sham procedure: after a Type A meeting in January 2026 the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; in 2026 it later sought alignment on a confirmatory design that included consideration of a randomized standard-of-care control instead of a sham procedure.
- Primary endpoint: the UHDRS TFC appears to have a ceiling effect in early stage Huntington's disease, and it lacks core clinimetric data on test-retest reliability and internal consistency.
- Timing: the FDA stated that the confirmatory study should be well underway, and potentially fully enrolled, at the time of accelerated approval; the company expects the study to be well underway by the time of potential approval.

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and); [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm); [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
